Resistance to monotherapy with BET bromodomain inhibitors has been observed and linked to kinome reprogramming in ovarian cancer (Kurimchak Alison et al, 2016) or to a decrease in PP2A activity in triple‐negative breast cancer (Shu et al, 2016). The gene discussed is PTPA; the disease is ovarian cancer.